Landon Capital

IRadimed Corporation (Nasdaq:IRMD) develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. With the goal of maintaining a high standard of care for critical patients, their products allow for seamless patient transport to and from MRIs. Their flagship products are non-magnetic, which allows them to expedite the MRI process. Therefore, accomplishing their goal to increase MRI efficiency and decrease the amount of time critical patients are away from their care unit.

Comps: Stereotaxis, Inc. (NYSE:STXS), OraSure Technologies, Inc. (Nasdaq:OSUR)

When looking to compare, IRadimed, from pure numbers standpoint, performs well in most vital categories. In relation to both of these enterprises, IRadimed outshines in earnings per share, price to earnings, profitability, return on equity, and debt to equity. Furthermore, they increased revenues more than Stereotaxis with 22.9% growth this quarter compared to that of last year.